
Zhejiang Xinguang Pharmaceutical Co., Ltd.
SZSE:300519.SZ
15.16 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 267.66 | 270.4 | 351.489 | 320.876 | 283.08 | 291.262 | 276.257 | 310.865 | 315.314 | 311.478 | 292.109 | 267.938 | 249.855 | 229.617 |
Cost of Revenue
| 177.117 | 158.795 | 169.232 | 142.133 | 126.533 | 132.079 | 124.48 | 123.722 | 109.536 | 106.457 | 106.994 | 119.774 | 134.57 | 139.9 |
Gross Profit
| 90.543 | 111.605 | 182.257 | 178.743 | 156.547 | 159.183 | 151.777 | 187.143 | 205.777 | 205.021 | 185.115 | 148.164 | 115.285 | 89.717 |
Gross Profit Ratio
| 0.338 | 0.413 | 0.519 | 0.557 | 0.553 | 0.547 | 0.549 | 0.602 | 0.653 | 0.658 | 0.634 | 0.553 | 0.461 | 0.391 |
Reseach & Development Expenses
| 12.624 | 15.134 | 15.549 | 13.52 | 12.01 | 15.897 | 17.774 | 17.694 | 15.109 | 14.109 | 11.311 | 12.849 | 0 | 0 |
General & Administrative Expenses
| 3.184 | 2.997 | 2.718 | 3.455 | 2.845 | 4.412 | 3.34 | 3.998 | 4.005 | 4.287 | 5.321 | 5.828 | 25.263 | 19.415 |
Selling & Marketing Expenses
| 18.394 | 19.531 | 33.739 | 32.061 | 32.477 | 30.468 | 28.699 | 32.253 | 36.187 | 33.487 | 31.753 | 32.475 | 24.962 | 25.019 |
SG&A
| 21.578 | 22.318 | 36.456 | 35.516 | 35.322 | 34.879 | 32.039 | 36.251 | 40.192 | 37.774 | 37.074 | 38.303 | 50.225 | 44.434 |
Other Expenses
| -1.004 | 0.019 | -1.001 | -0.626 | 2.303 | -0.359 | -0.185 | 0.014 | 6.544 | 0.498 | 1.034 | 2.127 | 6.378 | 0.359 |
Operating Expenses
| 33.198 | 37.471 | 69.102 | 68 | 63.047 | 65.696 | 64.887 | 70.85 | 75.676 | 70.256 | 66.535 | 65.669 | 53.14 | 46.626 |
Operating Income
| 57.346 | 74.133 | 126.605 | 132.583 | 112.494 | 108.632 | 101.043 | 122.512 | 132.014 | 137.604 | 122.083 | 82.332 | 60.028 | 56.117 |
Operating Income Ratio
| 0.214 | 0.274 | 0.36 | 0.413 | 0.397 | 0.373 | 0.366 | 0.394 | 0.419 | 0.442 | 0.418 | 0.307 | 0.24 | 0.244 |
Total Other Income Expenses Net
| -0.34 | -0.973 | 14.78 | 23.231 | 23.105 | 16.181 | 14.723 | 0.014 | 6.526 | 0.398 | 0.87 | 2.118 | 5.768 | 0.359 |
Income Before Tax
| 57.006 | 73.16 | 125.604 | 131.957 | 114.797 | 108.273 | 100.857 | 122.526 | 138.539 | 138.003 | 122.953 | 84.45 | 65.796 | 56.476 |
Income Before Tax Ratio
| 0.213 | 0.271 | 0.357 | 0.411 | 0.406 | 0.372 | 0.365 | 0.394 | 0.439 | 0.443 | 0.421 | 0.315 | 0.263 | 0.246 |
Income Tax Expense
| 6.616 | 8.804 | 16.783 | 17.677 | 15.821 | 14.372 | 12.862 | 16.367 | 19.58 | 19.219 | 17.301 | 11.981 | 8.95 | 8.35 |
Net Income
| 50.39 | 64.356 | 108.821 | 114.28 | 98.976 | 93.901 | 87.996 | 106.159 | 118.959 | 118.784 | 105.652 | 72.469 | 56.838 | 46.854 |
Net Income Ratio
| 0.188 | 0.238 | 0.31 | 0.356 | 0.35 | 0.322 | 0.319 | 0.341 | 0.377 | 0.381 | 0.362 | 0.27 | 0.227 | 0.204 |
EPS
| 0.32 | 0.4 | 0.68 | 0.71 | 0.62 | 0.59 | 0.55 | 0.66 | 0.89 | 0.99 | 0.88 | 0.61 | 0.48 | 1.56 |
EPS Diluted
| 0.32 | 0.4 | 0.68 | 0.71 | 0.62 | 0.59 | 0.55 | 0.66 | 0.89 | 0.99 | 0.88 | 0.61 | 0.48 | 1.56 |
EBITDA
| 49.31 | 63.708 | 127.84 | 128.207 | 106.308 | 103.687 | 94.754 | 128.567 | 144.512 | 144.054 | 128.984 | 87.607 | 62.617 | 40.551 |
EBITDA Ratio
| 0.184 | 0.236 | 0.364 | 0.4 | 0.376 | 0.356 | 0.343 | 0.414 | 0.458 | 0.462 | 0.442 | 0.327 | 0.251 | 0.177 |